|
Day 1 | Day
2
Scientific Advisory Board
Carole Jabet, Vice President, Affaires Scientifiques, Génome Québec
Michael Phillips, Ph.D., Director of Pharmacogenomics, Génome Québec
and Associate Professor, Université de Montréal
Wednesday, November 5
8:00am Short Course Registration
|
8:30 - 11:30am
Pre-conference Short Course
RE-SEQUENCING OF HUMAN GENES*
Cancer Genomic Applications of Human Genome Resequencing
John McPherson, Ph.D., Cancer Genomics Director & Senior Principal Investigator, Ontario Institute for Cancer Research
DNA sequencing technology is undergoing a revolution with increased throughput allowing, for the first time, large-scale comprehensive analysis of human genomes. In addition to the cataloging of single nucleotide variants, these same platforms are readily adapted to analyzing structural variants, expression analysis and epigenetic changes in tumours compared to matched normal samples.
Copy Number Variation
Richard F. Wintle, Ph.D., Assistant Director, The Centre for Applied
Genomics, Hospital for Sick Children
Novel technologies are enabling increasing discovery of structural and copy number variation in the genome. Hand-in-hand with next-generation DNA sequencing approaches, higher and higher density microarrays and low-throughput validation techniques such as quantitative PCR and cytogenomic technologies can be used to identify both common population variants and rare, disease-specific events. Efforts at The Centre for Applied Genomics focus on both ends of this spectrum: from cataloguing genomic variation in the general population, to teasing out disease-relevant genes within CNVs in autism spectrum disorders and rare dysmorphology syndromes.
Common Alleles Associated with Human Disease and Quantitative Traits
Tomi M. Pastinen, M.D., Ph.D., Assistant Professor, Canada Research in Human
Genomics, Departments of Human Genetics and Medical Genetics, McGill University and Génome Québec Innovation Centre
* Separate Registration Required |
| 11:30 Conference
Registration, Lunch On your Own
|
|
Session I:
SETTING THE STAGE FOR PHARMACOGENOMICS
1:00pm Chairperson’s Remarks
 Mr. Paul L’Archevêque, President and Chief Executive Officer,
Génome Québec
1:10 Future Directions
 Agnes V. Klein, M.D., Director, Health Products & Food Branch,
Health Canada
1:40 Differentiation of Medicines using Pharmacogenetics
 Lon R. Cardon, Ph.D., Head of Genetics, GlaxoSmithKline
Gene discovery for complex diseases has met unprecedented success over the past year. Pharmacogenetics has also experienced progress, though not at the same level. We need to understand how the emerging knowledge and the methods that have proven successful for complex disease genetics can be employed to facilitate drug discovery and development. Here we consider the role of genetics in specific points of intervention for differentiation of medicines.
2:15 Biomarker-Based Pharmacogenomic Strategies
 Richard D. Hockett, Medical Fellow II, Director
of Genomics, Eli Lilly & Co.
2:40 Development of a Translational Pharmacogenomics Platform: Integrating Genomic Research into Clinical Applications
 Michael Phillips, Ph.D., Director of Pharmacogenomics, Génome Québec, Associate Professor, Université de Montréal
To address the evolving challenges being encountered by the integration of pharmacogenomics into the clinical setting, we have developed a translational pharmacogenomics platform which takes advantage of industrial technology development and access to vast clinical populations while having the capability to support large pharmaceutical clinical trials in a Good Laboratory Practices (GLP) environment. This platform has the capability of accelerating the integration of research based observations into new clinical based applications. In support of its clinical trial work, the Centre is developing unique tools such as the construction of broad based panels that can look at >3000 ADME SNPs simultaneously and very focused FDA approved clinical genotyping panels that assess specific SNPs in key genes. We are also developing a responsive bioinformatics and medical informatics infrastructure that permits the analysis, interpretation, transfer and dissemination of pharmacogenomic data from the clinic to the laboratory and back to the physician (clinic) in a guidance-based format.
3:05 Spotlight Presentation
(Sponsorship Available)
3:35 Refreshment Break, Poster & Exhibit Viewing
4:10 Personalized Medicine:
A Vision for Personalized Healthcare
 Bernard M. Prigent, M.D., MBA, Vice President & Medical Director,
Pfizer Canada Inc
The recent evolution of genomics technology is providing researchers and healthcare professionals with the opportunity to deliver on the goals of personalized medicine. Over the next decade, the aggressive application of genomics, proteomics and metabolomics to the drug discovery and development process will lead to the introduction of targeted therapies for smaller, molecularly defined, patient populations. The successful development and commercialization of customized therapy solutions will require strong collaborations between industry, academia, regulators payers and patients.
4:35 The Value of Personalized Medicine: What is it, How Do We Measure it, and Why Should We Care?
 Kathryn A. Phillips, Ph.D. , Professor of Health Economics & Health Services Research, School of Pharmacy, Institute for Health
Policy Studies and UCSF Comprehensive Cancer Center, University of California, San Francisco
A key determinant of the appropriate adoption of personalized medicine will be whether its value is perceived to be worth its costs by patients, clinicians, regulators, industry, payers, and government. This presentation will use case studies to illustrate challenges and opportunities in determining the value of personalized medicine.
5:05 Expert Panel: How to Regulate Pharmacogenomics
Moderator: Mrs Marielle Gascon-Barré, per interim President at le “Fonds de recherche en santé du Québec” (FRSQ)
Agnes V. Klein, M.D.
Lawrence J. Lesko, Ph.D.
5:30 Networking Reception
Sponsored by 
6:30 Close of Day One
Day 1 | Day
2
|
